Analysts Set $25.67 Target Price for Quanterix Corp (QTRX)

Quanterix Corp (NASDAQ:QTRX) has been given an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus target price of $25.67 for the company and are predicting that the company will post ($0.26) EPS for the current quarter, according to Zacks. Zacks has also assigned Quanterix an industry rank of 173 out of 265 based on the ratings given to related companies.

Several equities analysts have weighed in on QTRX shares. JPMorgan Chase started coverage on shares of Quanterix in a report on Tuesday, January 2nd. They set an “overweight” rating for the company. Cowen started coverage on shares of Quanterix in a report on Tuesday, January 2nd. They set an “outperform” rating for the company. BTIG Research started coverage on shares of Quanterix in a report on Tuesday, January 2nd. They set a “buy” rating and a $26.00 target price for the company. Leerink Swann started coverage on shares of Quanterix in a report on Tuesday, January 2nd. They set an “outperform” rating and a $27.00 target price for the company. Finally, ValuEngine upgraded shares of Quanterix from a “sell” rating to a “hold” rating in a report on Monday, April 2nd.



NASDAQ:QTRX traded down $0.52 during mid-day trading on Thursday, hitting $16.09. 22,148 shares of the company’s stock traded hands, compared to its average volume of 126,862. The company has a current ratio of 4.53, a quick ratio of 4.35 and a debt-to-equity ratio of 0.07. Quanterix has a 1 year low of $15.56 and a 1 year high of $24.81. The company has a market capitalization of $357.58 and a P/E ratio of -1.94.

Several hedge funds and other institutional investors have recently modified their holdings of QTRX. Jennison Associates LLC purchased a new stake in shares of Quanterix during the fourth quarter worth about $6,353,000. Royce & Associates LP purchased a new stake in shares of Quanterix during the fourth quarter worth about $4,382,000. Opaleye Management Inc. purchased a new stake in shares of Quanterix during the fourth quarter worth about $1,395,000. Monashee Investment Management LLC purchased a new stake in shares of Quanterix during the fourth quarter worth about $3,811,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Quanterix during the fourth quarter worth about $720,000. Institutional investors and hedge funds own 42.36% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://dakotafinancialnews.com/2018/04/13/analysts-set-25-67-target-price-for-quanterix-corp-qtrx.html.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and SR-X system that supports the detection capability of approximately six biomarkers per test.

Get a free copy of the Zacks research report on Quanterix (QTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply